Albert Labs International (FRA:VB50) Notes Receivable: €0.00 Mil (As of Sep. 2023)


What is Albert Labs International Notes Receivable?

Albert Labs International FRA:VB50 Notes Receivable is €0.00 Mil as of Sep. 2023.

Albert Labs International's Notes Receivable for the quarter that ended in Sep. 2023 was €0.00 Mil.

Albert Labs International Notes Receivable Related Terms

Albert Labs International Notes Receivable Historical Data

* Premium members only.

The historical data trend for Albert Labs International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International Notes Receivable Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Notes Receivable
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Albert Labs International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Albert Labs International (FRA:VB50) has a Notes Receivable of €0.00 Mil as of Sep. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's Notes Receivable too high?
Albert Labs International's current Notes Receivable is €0.00 Mil.
How does Albert Labs International's Notes Receivable compare to VRTX and REGN?
Albert Labs International's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Albert Labs International and its competitors. Albert Labs International's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current Notes Receivable is €0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.